Compare · LIFE vs MEIP
LIFE vs MEIP
Side-by-side comparison of Ethos Technologies Inc. (LIFE) and MEI Pharma Inc. (MEIP): market cap, price performance, sector, and recent activity on the wire.
Summary
- LIFE operates in Finance, while MEIP operates in Health Care - the two are in different parts of the market.
- LIFE is the larger of the two at $1.06B, about 4.2x MEIP ($253.7M).
- Over the past year, LIFE is down 1.3% and MEIP is up 44.8% - MEIP leads by 46.1 points.
- LIFE has hit the wire 6 times in the past 4 weeks while MEIP has been quiet.
- LIFE has more recent analyst coverage (17 ratings vs 5 for MEIP).
- Company
- Ethos Technologies Inc.
- MEI Pharma Inc.
- Price
- $16.77-0.59%
- $3.06+9.50%
- Market cap
- $1.06B
- $253.7M
- 1M return
- -45.21%
- -37.14%
- 1Y return
- -1.29%
- +44.79%
- Industry
- Specialty Insurers
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- 2003
- News (4w)
- 6
- 0
- Recent ratings
- 17
- 5
Ethos Technologies Inc.
aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product, ATYR1923, is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
MEI Pharma Inc.
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.
Latest LIFE
- Ethos Partners with Baseball Legend David Ortiz to Champion Life Insurance as a Family Financial Essential
- President Wang Lingke sold $1,024,561 worth of shares (46,349 units at $22.11), decreasing direct ownership by 14% to 695,302 units (SEC Form 4) (withholding tax)
- CEO and Secretary Colis Peter George sold $1,324,783 worth of shares (60,035 units at $22.07), decreasing direct ownership by 14% to 695,302 units (SEC Form 4) to satisfy withholding obligation
- Chief Financial Officer Capozzi Christopher M. was granted 80,287 shares and sold $1,783,698 worth of shares (80,586 units at $22.13), decreasing direct ownership by 0.04% to 665,228 units (SEC Form 4) (tax liability)
- Chief Accounting Officer Kucharski Brandt Walter sold $128,435 worth of shares (5,823 units at $22.06) and was granted 56,769 shares, increasing direct ownership by 38% to 183,430 units (SEC Form 4) (for tax liability)
- Large owner Gv 2019 Gp, L.L.C. disposed of 147,552 shares and sold $3,459,809 worth of shares (147,552 units at $23.45) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Ethos Technologies Inc.
- SEC Form 144 filed by Ethos Technologies Inc.
- SEC Form 144 filed by Ethos Technologies Inc.
- SEC Form 144 filed by Ethos Technologies Inc.
Latest MEIP
- MEI Pharma Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- New insider Schornstein Alexander claimed ownership of 4,365,472 shares (SEC Form 3)
- MEI Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker 'LITS'
- SEC Form EFFECT filed by MEI Pharma Inc.
- SEC Form 424B3 filed by MEI Pharma Inc.
- MEI Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Amendment: SEC Form S-3/A filed by MEI Pharma Inc.
- SEC Form 4 filed by Director Riezman Joshua
- SEC Form 3 filed by new insider Riezman Joshua